Mitsubishi UFJ Trust & Banking Corp Has $81.59 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mitsubishi UFJ Trust & Banking Corp trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 588,337 shares of the medical device company’s stock after selling 35,538 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.15% of DexCom worth $81,585,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in DXCM. Dynamic Advisor Solutions LLC bought a new stake in shares of DexCom in the fourth quarter valued at about $260,000. Raymond James Trust N.A. boosted its position in DexCom by 333.6% during the 4th quarter. Raymond James Trust N.A. now owns 22,099 shares of the medical device company’s stock worth $2,742,000 after acquiring an additional 17,002 shares during the last quarter. FORVIS Wealth Advisors LLC grew its stake in shares of DexCom by 0.7% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares in the last quarter. Advisor Resource Council raised its holdings in shares of DexCom by 586.6% in the fourth quarter. Advisor Resource Council now owns 17,427 shares of the medical device company’s stock valued at $2,163,000 after purchasing an additional 14,889 shares during the last quarter. Finally, CX Institutional bought a new stake in shares of DexCom in the fourth quarter worth $286,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock valued at $480,861 in the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on DXCM shares. Canaccord Genuity Group lifted their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Redburn Atlantic initiated coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target on the stock. Stifel Nicolaus dropped their price objective on DexCom from $145.00 to $132.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $139.33.

DexCom Stock Performance

Shares of DexCom stock traded up $0.96 on Friday, hitting $111.66. The stock had a trading volume of 2,274,469 shares, compared to its average volume of 2,634,305. The stock has a market cap of $44.40 billion, a price-to-earnings ratio of 72.04, a price-to-earnings-growth ratio of 2.73 and a beta of 1.16. The business’s 50 day moving average is $118.01 and its two-hundred day moving average is $124.61. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.